^
No biomarker
Leiomyosarcoma
trabectedin
Sensitive
:
A1
No biomarker
Leiomyosarcoma
eribulin mesylate
Sensitive
:
A2
No biomarker
Leiomyosarcoma
doxorubicin hydrochloride + dacarbazine
Sensitive
:
A2
No biomarker
Leiomyosarcoma
PTC596
Sensitive
:
B
Chr amplification(4)(q22.1)
Leiomyosarcoma
eribulin mesylate
Resistant
:
C3
Chr del(3)(q14.2)
Leiomyosarcoma
eribulin mesylate
Resistant
:
C3
Chr del(11)(q25)
Leiomyosarcoma
eribulin mesylate
Resistant
:
C3
Chr del(2)(q14.1)
Leiomyosarcoma
eribulin mesylate
Resistant
:
C3
Chr del(2)(p12)
Leiomyosarcoma
eribulin mesylate
Sensitive
:
C3
Chr del(1)(q44)
Leiomyosarcoma
eribulin mesylate
Resistant
:
C3
Chr amplification(8)(q13.2)
Leiomyosarcoma
eribulin mesylate
Resistant
:
C3
Chr amplification(8)(q22.2)
Leiomyosarcoma
eribulin mesylate
Resistant
:
C3
Chr amplification(13)(q13.3)
Leiomyosarcoma
eribulin mesylate
Resistant
:
C3
Chr amplification(20)(p12.2)
Leiomyosarcoma
eribulin mesylate
Resistant
:
C3
Chr amplification(4)(q26)
Leiomyosarcoma
eribulin mesylate
Resistant
:
C3
ATRX mutation
Leiomyosarcoma
eribulin mesylate
Resistant
:
C3
TP53 mutation
Leiomyosarcoma
eribulin mesylate
Sensitive
:
C3
ATRX mutation
Leiomyosarcoma
dacarbazine
Resistant
:
C3
TP53 mutation
Leiomyosarcoma
dacarbazine
Resistant
:
C3
AKT1 mutation + mTOR mutation
Leiomyosarcoma
CB-228
Sensitive
:
C3
TMB-H
Leiomyosarcoma
nivolumab + ipilimumab
Sensitive
:
C3
MYH9-ALK + ALK-WDR43
Leiomyosarcoma
crizotinib
Sensitive
:
C4
PTEN mutation + TSC1 mutation
Leiomyosarcoma
CB-228
Sensitive
:
C4
NF1 mutation
Leiomyosarcoma
IPN60090
Sensitive
:
C4
YWHAE-JAZF1 fusion
Leiomyosarcoma
regorafenib
Sensitive
:
C4
PLK4 expression
Leiomyosarcoma
CFI-400945
Sensitive
:
D
CSPG4 overexpression
Leiomyosarcoma
CSPG4.TNK
Sensitive
:
D
HAT1 overexpression
Leiomyosarcoma
pazopanib
Resistant
:
D
MAN1A1-ROS1 rearrangement
Leiomyosarcoma
crizotinib
Sensitive
:
D
TP53 mutation
Leiomyosarcoma
selinexor + eribulin mesylate
Sensitive
:
D